viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals adds veteran pharma executive to its board

The specialty pharmaceutical company says Adele Gulfo’s addition enhances the board’s commercial and business development expertise

board room
Gulfo helped launch Lipitor, which became the world's best-selling medicine, and oversaw the launch and growth of Crestor

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCMKTS:PDDPF) said Tuesday it has appointed Adele M. Gulfo to the board of directors.

The specialty pharmaceutical company said Gulfo’s addition enhances the board’s commercial and business development expertise.

Gulfo is currently chief of commercial development at Roivant Sciences Ltd and was chief strategy officer of Mylan NV (NASDAQ:MYL) before that. She spent 14 years in various senior roles at Pfizer Inc (NYSE:PFE) and spent nine years AstraZeneca PLC (NYSE:AZN), where she ran the Cardiovascular and Diabetes Business Unit.

BIG PICTURE: Medexus Pharmaceuticals is commercializing a pipeline of more than 20 different drugs

Among her accomplishments, Gulfo helped launch Lipitor, which became the world's best-selling medicine with peak revenues of US$13.7 billion globally. She also oversaw the launch and growth of Crestor, which achieved peak sales of US$6 billion. She also ran teams that grew Toprol-XL to US$2 billion from US$200 million.

“We are thrilled to add Adele to our board of directors,” said Ken d’Entremont, CEO of Montreal-based Medexus, in a statement. “She brings deep global experience in both business development and commercialization of multi-billion-dollar products. Her knowledge and experience will be invaluable in helping guide the growth of our existing portfolio, as well as in identifying new products that can be added to our product pipeline as we continue on our rapid growth trajectory across North America.”

As a scientist, Gulfo holds eight US patents and serves as an advisory board member of Partners Healthcare (founded by Brigham and Women’s Hospital and Massachusetts General Hospital) and Springboard Life Sciences.

Contact Paul Curcio at [email protected]

Follow him on Twitter @GoCurcioGo

Quick facts: Medexus Pharmaceuticals Inc

Price: 4.1 CAD

Market: TSX-V
Market Cap: $59.25 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...



Medexus Pharmaceuticals reveals 4Q revenue surge

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQB:PDDPF) CEO Ken d’Entremont tells Proactive its fourth quarterly revenue doubled year-over-year thanks in large part to its February acquisition of Aptevo BioTherapeutics LLC. d’Entremont says the pharmaceutical company posted revenue of C$25.6...

on 06/24/2020

2 min read